IP Library Granted Patent US 7,482,445
Granted Patent B2
US 7,482,445 · App. 10/561,200 · Granted Jan 27, 2009

Crystalline carbapenem intermediate

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,482,445
App. No.
10/561,200
Granted
Jan 27, 2009
Kind
B2
Abstract

This invention relates to crystals of compounds of formula (I), wherein TBS represents t-butyldimethylsilyl, and Ph represents phenyl, or its salt or solvate. Compounds of formula (I) are synthesis intermediates of 2-substituted-1β-methyl carbapenem compounds useful as antimicrobial agents. The crystals of the present invention have excellent handleability and can realize the production of carbapenem compounds having excellent antimicrobial activity in a simpler manner with improved yield and purity.

Claims (22)

1. A crystal of a solvate of a compound of formula (I):

wherein TBS represents t-butyldimethylsilyl and Ph represents phenyl and the solvate is a hydrate, an alcoholate, an etherate or a solvate with an ester solvent.

2. The crystal according to claim 1 , which is a crystal of an alkyl acetate solvate of the compound of formula (I).

3. The crystal according to claim 1 , which is a crystal of an ethyl acetate solvate of the compound of formula (I).

4. The crystal according to claim 1 , comprising a powder X ray diffraction pattern having peaks at 10.2±0.1, 11.7±0.1, 17.0±0.1 and 21.5±0.1 degrees 2θ when measured using CuKα radiation.

5. The crystal according to claim 4 , comprising a powder X ray diffraction pattern having peaks at 10.2±0.1, 11.7±0.1, 11.9±0.1 17.0±0.1 and 21.5±0.1 degrees 2θ when measured using CuKα radiation.

6. The crystal according to claim 1 , which can be obtained by precipitating a crystal from a solution of the compound of formula (I) dissolved in ethyl acetate.

7. The crystal according to claim 1 , which is a crystal of a butyl acetate solvate of the compound of formula (I).

8. The crystal according to claim 1 , comprising a powder X ray diffraction pattern having peaks at 9.3±0.1, 12.5±0.2, 13.7±0.2 and 15.7±0.2 degrees 2θ when measured using CuKα radiation.

9. The crystal according to claim 8 , comprising a powder X ray diffraction pattern having peaks at 8.0±0.1, 9.3±0.1, 9.8±0.2, 12.5±0.2, 13.7±0.2 and 15.7 0.2 degrees 2θ when measured using CuKα radiation.

10. The crystal according to claim 1 , comprising a powder X ray diffraction pattern having peaks at 5.7±0.1, 11.2±0.2, 13.9±0.2 and 14.5±0.2 degrees 2θ when measured using CuKα radiation.

11. The crystal according to claim 10 , comprising a powder X ray diffraction pattern having peaks at 5.7±0.1, 8.4±0.1, 10.3±0.1, 11.2±0.2, 13.9±0.2 and 14.5±0.2 degrees 2θ when measured using CuKα radiation.

12. The crystal according to claim 1 , obtained by precipitating a crystal from a solution of the compound of formula (I) dissolved in butyl acetate or a mixture of butyl acetate with a solvent for crystallization.

13. The crystal according to claim 12 , wherein said solvent for crystallization is n-hexane or n-heptane.

14. The crystal according to claim 1 , obtained by dissolving the compound of formula (I) in a solvent selected from the group consisting of water, methanol, ethanol, propanol, isopropyl alcohol, n-butanol, diethyl ether, methyl acetate, propyl acetate, butyl acetate, and a mixture of any one of said solvents with a solvent for crystallization, and precipitating a crystal from the solution.

15. A process for producing a crystal according to claim 1 , said process comprising dissolving the compound of formula (I) in a solvent selected from the group consisting of water, methanol, ethanol, propanol, isopropyl alcohol, n-butanol, diethyl ether, methyl acetate, propyl acetate, butyl acetate, and a mixture of any one of said solvents with a solvent for crystallization, and precipitating a crystal from the solution.

16. The process according to claim 15 , wherein said solution and a separately provided solvent for crystallization are subjected to the procedure by a vapor diffusion method to precipitate a crystal.

17. The process according to claim 16 , wherein said procedure by the vapor diffusion method comprises allowing said solution and a separately provided solvent for crystallization to stand separately in respective hermetically sealable vessels in a volume ration of 1:1 to 1:20.

18. The process according to claim 15 , wherein said solvent for dissolving the compound of formula (I) is selected from the group consisting of ethyl acetate, butyl acetate, and a mixture of any one of said solvents with a solvent for crystallization.

19. The process according to claim 15 , wherein said solvent for crystallization is selected from the group consisting of n-pentane, n-hexane, n-heptane, cyclohexane, petroleum ether, diisopropyl ether, and diethyl ether.

20. The process according to claim 19 , wherein said solvent for crystallization is n-hexane or n-heptane.

21. The process according to claim 15 , comprising dissolving a non-crystalline solid compound of formula (I) in said solvent in ethyl acetate or butyl acetate, adding n-hexane or n-heptane, cooling the mixture, and optionally isolating and drying the resultant solid matter.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2011
From: MEIJI SEIKA KAISHA, LTD.
To: MEIJI SEIKA PHARMA CO., LTD.
Reel/Frame 027211/0418 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2005
From: AIHARA, KAZUHIRO; HASEGAWA, TOSHIFUMI; KITAHARA, SHINICHI; WATANABE, TAKASHI; ANDO, TAKASHI; SAWABE, TAKEHIKO; SHITARA, EIKI; ATSUMI, KUNIO; OTA, KAZUMI
To: MEIJI SEIKA KAISHA, LTD.
Reel/Frame 017389/0435 →